SPK 3006 - Emerging Drug Insight and Market Forecast – 2030
This report can be delivered to the clients within 48 Hours
“SPK 3006 - Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Pompe Disease in 7 Major Markets. A detailed picture of the SPK 3006 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Drug Summary
SPK-3006 is an investigational liver-directed AAV gene therapy for Pompe disease. SPK-3006 has been engineered to produce a modified enzyme that is secreted from the liver, which may sustain GAA plasma levels and lower immunogenicity to GAA to potentially provide greater uptake in muscle tissue. The transgene was in-licensed in 2017 from Genethon, a non-profit research and development organization dedicated to the development of gene therapies for orphan genetic diseases from research to clinical validation. Spark Therapeutics retains global commercialization rights to SPK-3006.
Scope of the report
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SPK 3006 Analytical Perspective by DelveInsight
Report highlights
“SPK 3006 - Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Pompe Disease in 7 Major Markets. A detailed picture of the SPK 3006 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Drug Summary
SPK-3006 is an investigational liver-directed AAV gene therapy for Pompe disease. SPK-3006 has been engineered to produce a modified enzyme that is secreted from the liver, which may sustain GAA plasma levels and lower immunogenicity to GAA to potentially provide greater uptake in muscle tissue. The transgene was in-licensed in 2017 from Genethon, a non-profit research and development organization dedicated to the development of gene therapies for orphan genetic diseases from research to clinical validation. Spark Therapeutics retains global commercialization rights to SPK-3006.
Scope of the report
The report provides insights into:
- A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
- Elaborated details on regulatory milestones and other development activities have been provided in this report.
- The report also highlights the drug research and development activity details across the United States, Europe and Japan.
- The report also covers the patents information with expiry timeline around SPK 3006.
- The report contains forecasted sales for SPK 3006 till 2030.
- Comprehensive coverage of the late-stage emerging therapies (Phase III) for Pompe Disease.
- The report also features the SWOT analysis with analyst insights and key findings of SPK 3006.
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SPK 3006 Analytical Perspective by DelveInsight
- In-depth SPK 3006 Market Assessment
- SPK 3006 Clinical Assessment
Report highlights
- In the coming years, the market scenario for Pompe Disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence SPK 3006 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Other emerging products for Pompe Disease are giving market competition to SPK 3006 and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of SPK 3006.
- Our in-depth analysis of the forecasted sales data of SPK 3006 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SPK 3006.
- Which company is developing SPK 3006 along with the phase of the clinical study?
- What is the technology utilized in the development of SPK 3006?
- What is the product type, route of administration and mechanism of action of SPK 3006?
- What is the clinical trial status of the study and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SPK 3006 development?
- What are the key designations that have been granted to SPK 3006?
- What is the forecasted market scenario of SPK 3006?
- What is the history of SPK 3006 and what is its future?
- What is the forecasted sales of SPK 3006 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available and how these are giving competition to SPK 3006?
- Which are the late-stage emerging therapies under development for the treatment of the PPD?
1. DRUG OVERVIEW
1.1. Product Detail
1.2. Mechanism of Action
1.3. Dosage and Administration
1.4. Research and development activity
1.4.1. Clinical Development
1.4.2. Safety and Efficacy
1.5. Other Development Activities
2. MARKET ASSESMENT
2.1. 7MM Market Analysis
2.2. The United States Market
2.3. Germany Market
2.4. France Market
2.5. Italy Market
2.6. Spain Market
2.7. United Kingdom Market
2.8. Japan Market
3. SWOT ANALYSIS
4. ANALYST VIEWS
5. MARKET COMPETITORS
6. OTHER EMERGING THERAPIES
7. APPENDIX
8. REPORT PURCHASE OPTIONS
1.1. Product Detail
1.2. Mechanism of Action
1.3. Dosage and Administration
1.4. Research and development activity
1.4.1. Clinical Development
1.4.2. Safety and Efficacy
1.5. Other Development Activities
2. MARKET ASSESMENT
2.1. 7MM Market Analysis
2.2. The United States Market
2.3. Germany Market
2.4. France Market
2.5. Italy Market
2.6. Spain Market
2.7. United Kingdom Market
2.8. Japan Market
3. SWOT ANALYSIS
4. ANALYST VIEWS
5. MARKET COMPETITORS
6. OTHER EMERGING THERAPIES
7. APPENDIX
8. REPORT PURCHASE OPTIONS
LIST OF TABLES
Table 1 SPK 3006, Description
Table 2 SPK 3006, Clinical Trial Description
Table 3 SPK 3006, 7MM Market Size from 2020 to 2030 (in Million USD)
Table 4 Market Competitors
Table 5 Other Emerging Therapies
Table 1 SPK 3006, Description
Table 2 SPK 3006, Clinical Trial Description
Table 3 SPK 3006, 7MM Market Size from 2020 to 2030 (in Million USD)
Table 4 Market Competitors
Table 5 Other Emerging Therapies
LIST OF FIGURES
Figure 1 The Development Timeline of SPK 3006
Figure 2 Patent Details, SPK 3006
Figure 3 SPK 3006, 7MM Market Size from 2020 to 2030 (in Million USD)
Figure 4 SPK 3006, US Market Size from 2020 to 2030 (in Millions USD)
Figure 5 SPK 3006, EU5 Market Size from 2020 to 2030 (in Millions USD)
Figure 6 SPK 3006, Japan Market Size from 2020 to 2030 (in Millions USD)
Figure 1 The Development Timeline of SPK 3006
Figure 2 Patent Details, SPK 3006
Figure 3 SPK 3006, 7MM Market Size from 2020 to 2030 (in Million USD)
Figure 4 SPK 3006, US Market Size from 2020 to 2030 (in Millions USD)
Figure 5 SPK 3006, EU5 Market Size from 2020 to 2030 (in Millions USD)
Figure 6 SPK 3006, Japan Market Size from 2020 to 2030 (in Millions USD)
